Consolidation could then be individualized based on the patients' immune response against ALK as measured by either the ‘control’ of disease by MRD or the existence of ALK‐specific T cells and may include vaccination with ALK epitopes (either mRNA or peptides) or a low‐toxicity allogeneic HSCT based on the individual immune response against the lymphoma. Here, ALK is linked to lymphoma.